

Julien Hadoux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3006250/publications.pdf>

Version: 2024-02-01

50
papers

1,528
citations

516710

16
h-index

315739

38
g-index

59
all docs

59
docs citations

59
times ranked

2203
citing authors

#	ARTICLE	IF	CITATIONS
1	Are G3 ENETS neuroendocrine neoplasms heterogeneous?. <i>Endocrine-Related Cancer</i> , 2013, 20, 649-657.	3.1	275
2	<i>SDHB</i> mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. <i>International Journal of Cancer</i> , 2014, 135, 2711-2720.	5.1	155
3	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	7.0	132
4	Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. <i>Endocrine-Related Cancer</i> , 2015, 22, 289-298.	3.1	119
5	Management of advanced medullary thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 64-71.	11.4	100
6	Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1109-1118.	3.6	82
7	Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1772-1780.	6.4	62
8	Anaplastic Thyroid Carcinoma: An Update. <i>Cancers</i> , 2022, 14, 1061.	3.7	47
9	Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. <i>European Journal of Cancer</i> , 2017, 75, 259-267.	2.8	39
10	Renal Cell Carcinoma: Focus on Safety and Efficacy of Temezirolimus. <i>Clinical Medicine Insights: Oncology</i> , 2010, 4, CMO.S4482.	1.3	38
11	Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 335-347.	4.7	38
12	Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 993-1002.	1.1	37
13	ATP6AP2 variant impairs CNS development and neuronal survival to cause fulminant neurodegeneration. <i>Journal of Clinical Investigation</i> , 2019, 129, 2145-2162.	8.2	37
14	Redifferentiation of a <i>BRAF</i> ^{K601E} -Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment. <i>Thyroid</i> , 2019, 29, 735-742.	4.5	35
15	F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients. <i>Thyroid</i> , 2019, 29, 1457-1464.	4.5	24
16	Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma. <i>Endocrine</i> , 2018, 59, 547-554.	2.3	22
17	Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer. <i>Cancers</i> , 2020, 12, 3282.	3.7	18
18	Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. <i>Cancers</i> , 2021, 13, 5366.	3.7	17

#	ARTICLE	IF	CITATIONS
19	Intervention in gastro-enteropancreatic neuroendocrine tumours. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 855-865.	2.4	16
20	Differentiated Thyroid Cancer in Children and Adolescents: Long Term Outcome and Risk Factors for Persistent Disease. <i>Cancers</i> , 2021, 13, 3732.	3.7	16
21	Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. <i>Hormones and Cancer</i> , 2017, 8, 330-337.	4.9	15
22	Transcriptional landscape of a RET C634Y -mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR1 transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers. <i>Stem Cell Research</i> , 2018, 26, 8-16.	0.7	15
23	Occult Contralateral Lateral Lymph Node Metastases in Unilateral N1b Papillary Thyroid Carcinoma. <i>World Journal of Surgery</i> , 2019, 43, 818-823.	1.6	15
24	Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?. <i>Annals of Oncology</i> , 2011, 22, 487-490.	1.2	13
25	Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2A (MEN2A) syndrome with RET mutation. <i>Stem Cell Research</i> , 2016, 17, 154-157.	0.7	13
26	Risk-oriented concept of treatment for intrathyroid papillary thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101281.	4.7	13
27	Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma. <i>European Journal of Radiology</i> , 2019, 119, 108650.	2.6	12
28	Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. <i>Endocrine-Related Cancer</i> , 2021, 28, 15-26.	3.1	12
29	Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 537-546.	2.5	12
30	Surgery in the context of kinase inhibitor therapy for locally invasive thyroid cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 650-655.	1.0	9
31	FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin. <i>Digestive and Liver Disease</i> , 2021, 53, 824-829.	0.9	9
32	Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. <i>European Journal of Cancer</i> , 2021, 152, 100-115.	2.8	9
33	Functional imaging in thyroid cancer patients with metastases and therapeutic implications. <i>Presse Medicale</i> , 2022, 51, 104113.	1.9	9
34	Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2726-2737.	3.6	8
35	Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 Patients. <i>Bulletin Du Cancer</i> , 2013, 100, E30-E37.	1.6	6
36	Multimodal Treatment With Doxorubicin, Cisplatin, and Ifosfamide for the Treatment of Advanced or Metastatic Uterine Leiomyosarcoma: A Unicentric Experience. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 296-302.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Bevacizumab and Subtype-Adapted Chemotherapy Backbone in Neuroendocrine Tumors. Journal of Clinical Oncology, 2013, 31, 976-977.	1.6	5
38	Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma. Endocrine Connections, 2020, 9, 498-505.	1.9	5
39	Long-Term Results after Surgical Resection of Peritoneal Metastasis from Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 599-608.	2.5	3
40	Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity?. Neuroendocrinology, 2021, 111, 139-145.	2.5	3
41	Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with "highest risk" RET mutation. Stem Cell Research, 2017, 23, 154-157.	0.7	1
42	Preoperative ultrasound mapping of the vagus nerve in thyroid surgery. Gland Surgery, 2022, 11, 91-99.	1.1	1
43	Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival. Cancers, 2022, 14, 2225.	3.7	1
44	Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer. Expert Opinion on Investigational Drugs, 2022, 31, 669-679.	4.1	1
45	Brèves de l'EAERIO. Oncologie, 2012, 14, 553-556.	0.7	0
46	Déficit en fumarate hydratase, altération synthétique et métabolisme tumoral. Oncologie, 2012, 14, 271-272.	0.7	0
47	Essai BOLERO-2 Everolimus en association à l'exemestane pour le traitement des femmes ménopausées atteintes de cancer du sein métastatique exprimant les récepteurs hormonaux. Oncologie, 2012, 14, 349-352.	0.7	0
48	American association for cancer research " AACR congress 2014. Oncologie, 2014, 16, 341-366.	0.7	0
49	AERIO News in Brief. Oncologie, 2014, 16, 207-210.	0.7	0
50	A diffuse pruriginous erythematous-squamous rash. Endocrine, 2021, 74, 435-436.	2.3	0